巴瑞替尼对比地塞米松治疗成人COVID-19住院患者(ACTT-4)
ACTT-4是一项随机双盲双模拟试验,纳入1010例需低流量、高流量或无创通气补氧的COVID-19住院成人,比较巴瑞替尼+瑞德西韦与地塞米松+瑞德西韦。
要点
- 巴瑞替尼+瑞德西韦与地塞米松+瑞德西韦第29天无机械通气生存率相似。
- 地塞米松组至少一种不良事件、治疗相关不良事件及3/4级不良事件均显著更多。
- 免疫调节选择可个体化,考虑副作用、给药便利性、成本和合并症。
核心结论
- 在需低流量、高流量或无创通气补氧的COVID-19住院成人中,巴瑞替尼+瑞德西韦与地塞米松+瑞德西韦第29天无机械通气生存率相似。
- 地塞米松+瑞德西韦组不良事件、治疗相关不良事件及严重或危及生命的不良事件显著更多。
研究设计与样本
- 随机、双盲、双安慰剂对照试验,在美国60个、韩国2个、墨西哥2个、新加坡2个、日本1个共67个中心开展。
- 纳入1010例≥18岁实验室确诊SARS-CoV-2感染且需低流量(≤15 L/min)、高流量(>15 L/min)或无创机械通气的住院成人,1:1随机分配。
- 所有患者接受瑞德西韦(≤10天)联合巴瑞替尼(或口服安慰剂,最长14天)或地塞米松(或静脉安慰剂,最长10天)。
- 主要结局为改良意向治疗人群中第29天无机械通气生存的组间差异;安全性在 as-treated 人群中分析。
临床怎么用
- 对于需低流量、高流量或无创通气补氧的COVID-19住院成人,巴瑞替尼+瑞德西韦与地塞米松+瑞德西韦均可作为免疫调节选择。
- 选择免疫调节方案时可个体化考虑副作用特征、给药便利性、成本和患者合并症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19. METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), and Japan (one site). Hospitalised adults (≥18 years) with COVID-19 who required supplemental oxygen administered by low-flow (≤15 L/min), high-flow (>15 L/min), or non-invasive mechanical ventilation modalities who met the study eligibility criteria (male or non-pregnant female adults ≥18 years old with laboratory-confirmed SARS-CoV-2 infection) were enrolled in the study. Patients were randomly assigned (1:1) to receive either baricitinib, remdesivir, and placebo, or dexamethasone, remdesivir, and placebo using a permuted block design. Randomisation was stratified by study site and baseline ordinal score at enrolment. All patients received remdesivir (≤10 days) and either baricitinib (or matching oral placebo) for a maximum of 14 days or dexamethasone (or matching intravenous placebo) for a maximum of 10 days. The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population. Safety analyses were done in the as-treated population, comprising all participants who received one dose of the study drug. The trial is registered with ClinicalTrials.gov, NCT04640168. FINDINGS: Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (49%) to dexamethasone plus remdesivir plus placebo. The mean age of the patients was 58·3 years (SD 14·0) and 590 (58%) of 1010 patients were male. 588 (58%) of 1010 patients were White, 188 (19%) were Black, 70 (7%) were Asian, and 18 (2%) were American Indian or Alaska Native. 347 (34%) of 1010 patients were Hispanic or Latino. Mechanical ventilation-free survival by day 29 was similar between the study groups (Kaplan-Meier estimates of 87·0% [95% CI 83·7 to 89·6] in the baricitinib plus remdesivir plus placebo group and 87·6% [84·2 to 90·3] in the dexamethasone plus remdesivir plus placebo group; risk difference 0·6 [95% CI -3·6 to 4·8]; p=0·91). The odds ratio for improved status in the dexamethasone plus remdesivir plus placebo group compared with the baricitinib plus remdesivir plus placebo group was 1·01 (95% CI 0·80 to 1·27). At least one adverse event occurred in 149 (30%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 179 (37%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·5% [1·6 to 13·3]; p=0·014). 21 (4%) of 503 patients in the baricitinib plus remdesivir plus placebo group had at least one treatment-related adverse event versus 49 (10%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 6·0% [2·8 to 9·3]; p=0·00041). Severe or life-threatening grade 3 or 4 adverse events occurred in 143 (28%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 174 (36%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·7% [1·8 to 13·4]; p=0·012). INTERPRETATION: In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events. A more individually tailored choice of immunomodulation now appears possible, where side-effect profile, ease of administration, cost, and patient comorbidities can all be considered. FUNDING: National Institute of Allergy and Infectious Diseases.
引用
- Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022. PMID: 35617986. doi:10.1016/S2213-2600(22)00088-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。